Molecular Mechanisms of Disease Relapse After Allogenic Stem Cell Transplantation in MDS Patients

Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorGruppo Italiano Malattie EMatologiche dell'Adulto

About this trial

This is a biological study for adult MDS patients who undergo HSCT procedure. Viable bone marrow samples will be collected and cryopreserved from MDS patients before transplantation and at clinical disease recurrence. CD34+ blast cells at disease relapse after HSCT will be compared with CD34+ cells collected before transplant to study genomic and transcriptomic changes.

Eligibility criteria

Qualifiers

Diagnosis of MDS according to 2016 WHO criteria

Aged 18y or older

Patients who will receive allogeneic stem cell transplantation (HSCT)

Signed written informed consent according to ICH/EU/GCP and national local laws

Disqualifiers

Second HSCT procedure.

Trial design

Treatments tested in this trial

  • bone marrow withdrawal

Treatment groups

38 Participants
are divided into 1 treatment group